Published in Carcinogenesis on February 23, 2011
MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer (2012) 2.78
miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res (2012) 2.13
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Epigenetic modifications in cancer. Clin Genet (2011) 1.53
MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One (2013) 1.15
miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther (2014) 1.13
miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget (2014) 1.08
MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H₂O₂)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS One (2012) 1.08
MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med (2014) 1.08
MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int (2013) 1.05
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia (2013) 1.02
The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer (2013) 1.01
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol (2014) 0.98
MicroRNAs in prostate cancer. Prostate Int (2012) 0.96
Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int (2015) 0.96
MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation. PLoS One (2013) 0.92
Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol (2014) 0.92
MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res (2012) 0.91
miR-145 inhibits isoproterenol-induced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6. FEBS Lett (2013) 0.90
Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics (2011) 0.89
MicroRNA profiling of novel African American and Caucasian Prostate Cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase 1. Oncotarget (2014) 0.87
New insights into p53 functions through its target microRNAs. J Mol Cell Biol (2014) 0.87
The interaction between epigenetics, nutrition and the development of cancer. Nutrients (2015) 0.87
Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis (2015) 0.86
Noncoding RNAs in DNA repair and genome integrity. Antioxid Redox Signal (2013) 0.86
Targeting oncogenic PLCE1 by miR-145 impairs tumor proliferation and metastasis of esophageal squamous cell carcinoma. Oncotarget (2016) 0.86
Non-coding RNAs in lung cancer. Oncoscience (2014) 0.83
Genetic networks lead and follow tumor development: microRNA regulation of cell cycle and apoptosis in the p53 pathways. Biomed Res Int (2014) 0.82
microRNA Regulation and Its Consequences in Cancer. Curr Pathobiol Rep (2012) 0.82
DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. Cancer Res (2016) 0.81
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues. Biomed Res Int (2013) 0.81
The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel) (2013) 0.81
MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget (2016) 0.80
Epigenetic analysis of laser capture microdissected fetal epithelia. Anal Biochem (2013) 0.80
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics (2011) 0.80
MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans. Biotech Histochem (2013) 0.80
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget (2016) 0.80
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis. Prostate Int (2015) 0.79
Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications. Dis Markers (2015) 0.79
The Role of microRNAs in Stemness of Cancer Stem Cells. Oncol Rev (2013) 0.78
miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget (2016) 0.78
The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma. J Hum Genet (2016) 0.77
The role of microRNAs in prostate cancer progression. Transl Androl Urol (2013) 0.77
Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer. Br J Cancer (2017) 0.77
20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer. Oncotarget (2017) 0.77
miRNA Expression Analyses in Prostate Cancer Clinical Tissues. J Vis Exp (2015) 0.76
A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas. Lab Invest (2016) 0.76
Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. Anticancer Agents Med Chem (2016) 0.75
Loss-of-function screening to identify miRNAs involved in senescence: tumor suppressor activity of miRNA-335 and its new target CARF. Sci Rep (2016) 0.75
The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget (2017) 0.75
Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation, migration and invasion by targeting mucin 1. Cancer Biol Ther (2015) 0.75
MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro. Onco Targets Ther (2017) 0.75
miRNAs associated with prostate cancer risk and progression. BMC Urol (2017) 0.75
microRNAs and Prostate Cancer. Adv Exp Med Biol (2015) 0.75
Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies. World J Surg Oncol (2014) 0.75
Mapping the methylation status of the miR-145 promoter in saphenous vein smooth muscle cells from individuals with type 2 diabetes. Diab Vasc Dis Res (2016) 0.75
Interactions between the spike code and the epigenetic code during information processing in the brain. Front Mol Neurosci (2013) 0.75
Adipose Derived Stem Cells Affect miR-145 and p53 Expressions of Co-Cultured Hematopoietic Stem Cells. Cell J (2017) 0.75
Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer. Oncotarget (2017) 0.75
Mechanisms of miR-145 regulating invasion and metastasis of ovarian carcinoma. Am J Transl Res (2017) 0.75
Identification of novel genes coding for small expressed RNAs. Science (2001) 44.44
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009) 10.26
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell (2009) 8.14
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol (2004) 6.99
Widespread deregulation of microRNA expression in human prostate cancer. Oncogene (2007) 5.70
Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 5.25
p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A (2009) 5.05
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer (2010) 4.53
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle (2008) 4.35
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
p53 enters the microRNA world. Cancer Cell (2007) 3.78
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer (2009) 3.15
MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res (2009) 2.64
Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci (2007) 2.61
Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem (2007) 2.55
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
Prevalent mutations in prostate cancer. J Cell Biochem (2006) 2.12
CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle (2007) 2.12
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer (2006) 2.05
Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer (2005) 1.87
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle (2007) 1.71
Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res (2009) 1.68
Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate (2008) 1.46
MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab (2008) 1.33
MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res (2010) 1.26
Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer (2005) 1.06
The microRNA and p53 families join forces against cancer. Cell Death Differ (2010) 0.91
Micro RNA profiling: an easy and rapid method to screen and characterize stem cell populations. Methods Mol Biol (2007) 0.91
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
MethPrimer: designing primers for methylation PCRs. Bioinformatics (2002) 14.48
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 11.14
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A (2008) 6.38
Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A (2006) 4.90
IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med (2007) 3.69
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol (2012) 3.32
From molecular to macroscopic via the rational design of a self-assembled 3D DNA crystal. Nature (2009) 3.18
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol (2012) 3.09
Hormonal, cellular, and molecular control of prostatic development. Dev Biol (2003) 2.67
Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol (2005) 2.40
IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 2.39
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell (2003) 2.31
Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. Arch Pathol Lab Med (2008) 2.18
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med (2010) 2.13
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res (2010) 2.07
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. Arch Pathol Lab Med (2014) 2.02
Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol (2015) 2.02
Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol (2006) 1.95
E protein silencing by the leukemogenic AML1-ETO fusion protein. Science (2004) 1.89
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res (2005) 1.85
MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell (2005) 1.85
'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction (2007) 1.85
DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog (2002) 1.83
Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. Neurosci Lett (2009) 1.78
Chiral separation of tamsulosin isomers by HPLC using cellulose tris (3,5-dimethhylphenylcarbamate) as a chiral stationary phase. J Pharm Biomed Anal (2004) 1.75
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther (2006) 1.70
MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer (2010) 1.70
Structural basis for modulation of Kv4 K+ channels by auxiliary KChIP subunits. Nat Neurosci (2006) 1.70
Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer (2011) 1.69
Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med (2008) 1.69
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci (2010) 1.67
Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev (2015) 1.67
Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med (2009) 1.67
Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) (2013) 1.66
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
A DNAzyme that walks processively and autonomously along a one-dimensional track. Angew Chem Int Ed Engl (2005) 1.65
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res (2006) 1.65
The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity (2010) 1.64
Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol (2011) 1.63
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur Urol (2006) 1.63
Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology (2012) 1.62
In vivo oxygen radical generation in the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study. J Invest Dermatol (2004) 1.60
Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis (2005) 1.59
Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer (2008) 1.58
Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res (2008) 1.58
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Robust discrimination between self and non-self neurites requires thousands of Dscam1 isoforms. Nature (2009) 1.54
Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS (2007) 1.53
Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc (2012) 1.50
Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood (2008) 1.50
Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology (2005) 1.48
Emergency embolectomy for treatment of acute middle cerebral artery occlusion. J Neurosurg (2007) 1.47
Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol (2009) 1.47
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res (2012) 1.46
BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer (2006) 1.46
Impact of warming blood transfusion and infusion toward cerebral oxygen metabolism and cognitive recovery in the perioperative period of elderly knee replacement. J Orthop Surg Res (2014) 1.45
Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer (2008) 1.45
BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis (2009) 1.44
Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage (2010) 1.44